Meiling Chen

Jul 16, 2024 | cell.com | Meiling Chen |Chao Shen |Yi Chen |Zhenhua Chen

Highlights • Metformin substantially sensitizes FLT3-mutated AML cells to gilteritinib in vitro • Metformin synergizes with gilteritinib in treating FLT3-ITD AML in vivo • Metformin and gilteritinib cooperatively target PLK1/STAT5-ERK-mTOR in FLT3-ITD AML • Metformin plus TKI offers a potent and cost-effective therapy for FLT3-ITD AML Summary Fms-like tyrosine kinase 3 (FLT3) mutations, present in over 30% of acute myeloid leukemia (AML) cases and dominated by FLT3-internal tandem duplication...

Jun 25, 2024 | mdpi.com | Guofu Wang |Wei Zhang |Meiling Chen |Min Ji

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.